Clinical Trials
3 trialsNCT04220203 2025-06-26
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
Seagen Inc.
Approved for marketing
NCT03133988 2025-02-14
Margetuximab Expanded Access Program
TerSera Therapeutics LLC
Approved for marketing
NCT04395508 2022-07-05
An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
Genentech, Inc.
Approved for marketing